Clinical Trials Logo

Narcolepsy Type 1 (NT1) clinical trials

View clinical trials related to Narcolepsy Type 1 (NT1).

Filter by:
  • None
  • Page 1

NCT ID: NCT06462404 Not yet recruiting - Clinical trials for Narcolepsy Type 1 (NT1)

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

Start date: June 12, 2024
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy of single oral doses of E2086 compared to placebo in the treatment of excessive daytime sleepiness (EDS) as assessed by the Maintenance of Wakefulness Test (MWT) in adult participants with narcolepsy type 1 (NT1).

NCT ID: NCT04096560 Terminated - Clinical trials for Narcolepsy Type 1 (NT1)

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Start date: February 27, 2020
Phase: Phase 2
Study type: Interventional

The main aims of the study are: - To check for side effects from TAK-994 and check what dose of TAK-994 participants can tolerate. - To check what dose range provides adequate relief of narcolepsy symptoms. - To check how much TAK-994 stays in the blood of participants, over time. The study will have 4 parts. Participants can only join 1 of the parts. A. Participants with type 1 narcolepsy will take either TAK-994 or placebo tablets for 28 days. A placebo looks just like TAK-994 but will not have any medicine in it. B. Participants with type 1 narcolepsy will take 1 of 3 doses of TAK-994 or placebo tablets for 56 days. C. Participants with type 1 narcolepsy in China only will take TAK-994 or placebo tablets for 56 days. D. Participants with type 2 narcolepsy will take either TAK-994 or placebo tablets for 28 days.